Ratings BML, Inc.

Equities

4694

JP3799700004

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
2,908 ^JPY	0.00%		+0.52%	-3.07%

May. 03	Boab Metals Raising AU$5 Million to Advance Sorby Hills Lead-Silver-Zinc Project; Shares Down 8%	MT
Mar. 22	Matsa Resources Receives More High-Grade Gold Assays from Devon Pit Mine in Western Australia; Shares Down 3%	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.26 for the 2024 fiscal year.
The company appears to be poorly valued given its net asset value.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
BML, INC.	-3.07%	741M	-
SONIC HEALTHCARE LIMITED	-18.58%	8.3B	B+
RADNET, INC.	+47.25%	3.78B	C+
SYNLAB AG	-8.58%	2.47B	-
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-38.71%	2.46B	B-
DR. LAL PATHLABS LIMITED	-10.06%	2.31B	B-
NEOGENOMICS, INC.	-5.44%	1.95B	C-
FLEURY S.A.	-17.79%	1.59B	A-
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.78%	1.21B	C+
METROPOLIS HEALTHCARE LIMITED	+6.69%	1.1B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes